Hikma Secures Health Canada Approval for KLOXXADO Nasal Spray
LONDON and GAITHERSBURG, Md. — Hikma Pharmaceuticals PLC has announced that Health Canada has given the green light for KLOXXADO (naloxone HCl) Nasal Spray 8 mg. This critical medication is intended for managing suspected or known opioid overdoses, especially relevant for adult patients dealing with respiratory and/or central nervous system depression brought on by opioid consumption.
What is KLOXXADO?
KLOXXADO delivers an effective dosage of 8 mg of naloxone hydrochloride through a ready-to-use nasal spray. This formulation effectively negates the life-threatening impacts of opioid overdoses, providing immediate assistance until professional medical help can be administered.
“The approval of KLOXXADO Nasal Spray brings a vital option for Canadians grappling with the opioid crisis,” stated Hafrun Fridriksdottir, President of Hikma Generics. “With the alarming rise of perilous synthetic opioids, including illicit fentanyl, having an accessible nasal spray could serve as a pivotal intervention for those affected by overdose situations.”
Sales and Distribution Under Emergent BioSolutions
KLOXXADO will be marketed by Emergent BioSolutions as part of a newly formed six-year agreement with Hikma. As per this arrangement, Emergent will oversee all sales and marketing efforts throughout North America, while Hikma will manufacture KLOXXADO at its production facility in Columbus, Ohio. Emergent aims to have KLOXXADO available by prescription as early as 2026, reaching out to Canadian health agencies and private insurers to facilitate this.
The Urgent Need for Opioid Reversal Options
Paul Williams, SVP and head of products at Emergent, emphasized the gravity of the opioid crisis by noting that in 2023, Canada lost an alarming average of 22 lives daily to opioid overdoses. With medications like NARCAN, which has stood out as a 4 mg naloxone solution, the introduction of KLOXXADO may pave the way for more patients to receive higher dose treatments in emergency situations.
Research from Health Canada indicates a decrease in overdose mortality rates for the past three years, with naloxone distribution cited as a contributing factor. The availability of naloxone kits is vital in reversing thousands of overdoses across the nation. KLOXXADO is anticipated to enhance these efforts, granting healthcare providers and community members another powerful tool in their efforts against opioid-related fatalities.
Understanding Naloxone: The Active Component
Naloxone hydrochloride functions as an opioid antagonist. It competes with opioids at receptor sites, effectively counteracting opioid effects related to respiratory issues, sedation, and hypotension. Its ease of administration and effectiveness has made naloxone a mainstay in opioid overdose treatment protocols within healthcare settings in locations like the United States.
Patient and Community Education
It's essential for individuals who might find themselves in a situation where KLOXXADO is needed to know how to administer it. Family members and caregivers should store KLOXXADO within easy reach and familiarize themselves with its use to allow timely intervention during an opioid overdose emergency. Immediate medical intervention remains crucial even after administering KLOXXADO, as additional medical support may be necessary.
Commitment to Public Health
Hikma Pharmaceuticals has made significant strides in enhancing healthcare access globally for over 45 years, focusing on producing high-quality medicines. With its headquarters in the UK, the company operates across North America, the Middle East, North Africa, and Europe, bringing innovative solutions to the market. The approval of KLOXXADO is a testament to Hikma’s ongoing dedication to tackling public health challenges and providing tools for healthcare professionals and those in crisis.
Contact Information
For further inquiries, individuals may reach out to Steve Weiss, US Communications and Public Affairs at +1 732 788 8279. Alternatively, Assal Hellmer serves as Vice President of Communications and can be contacted for media-related questions.
Frequently Asked Questions
What is KLOXXADO?
KLOXXADO is a naloxone nasal spray designed to treat opioid overdoses by reversing the effects of opioids on the respiratory system.
How does KLOXXADO work?
This medication works by displacing opioids from their receptors in the brain, effectively counteracting respiratory depression and restoring normal breathing.
When will KLOXXADO be available in Canada?
Emergent aims to make KLOXXADO available by prescription in Canada as early as 2026.
Are there any side effects associated with KLOXXADO?
Potential side effects include withdrawal symptoms such as body aches and rapid heartbeat, among others. A full list is provided in the medication guide.
Where can I learn more about Hikma Pharmaceuticals?
More information about Hikma and its commitment to public health can be found on their official website.
